Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Prelude Therapeutics (PRLD) Return on Assets (2024 - 2026)

Prelude Therapeutics' Return on Assets history spans 3 years, with the latest figure at 0.01% for Q1 2026.

  • On a quarterly basis, Return on Assets changed 0.0% to 0.01% in Q1 2026 year-over-year; TTM through Mar 2026 was 0.01%, a 0.0% change, with the full-year FY2025 number at 0.01%, changed 0.0% from a year prior.
  • Return on Assets hit 0.01% in Q1 2026 for Prelude Therapeutics, up from 0.01% in the prior quarter.
  • Over the last five years, Return on Assets for PRLD hit a ceiling of 0.01% in Q3 2024 and a floor of 0.01% in Q3 2025.
  • Historically, Return on Assets has averaged 0.01% across 3 years, with a median of 0.01% in 2025.
  • The widest YoY moves for Return on Assets: up 0bps in 2025, down -1bps in 2025.
  • Tracing PRLD's Return on Assets over 3 years: stood at 0.01% in 2024, then decreased by -18bps to 0.01% in 2025, then grew by 27bps to 0.01% in 2026.
  • Business Quant data shows Return on Assets for PRLD at 0.01% in Q1 2026, 0.01% in Q4 2025, and 0.01% in Q3 2025.